These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28981164)

  • 1. Impact of Federal Regulatory Changes on Clinical Pharmacology and Drug Development: the Common Rule and the 21st Century Cures Act.
    Burris JF; Puglisi JT
    J Clin Pharmacol; 2018 Mar; 58(3):281-285. PubMed ID: 28981164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTSA Institution Responses to Proposed Common Rule Changes: Did They Get What They Wanted?
    Rivera SM; Nichols L; Brako L; Croft G; Russo T; Tran T
    J Empir Res Hum Res Ethics; 2017 Apr; 12(2):79-86. PubMed ID: 28421883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and Improved? 21
    Wolf LE; Beskow LM
    Am J Law Med; 2018 May; 44(2-3):343-358. PubMed ID: 30106660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
    Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of Common Rule Changes to the Informed Consent Form: A Research Staff and Institutional Review Board Collaboration.
    Gartel G; Scuderi H; Servay C
    Ochsner J; 2020; 20(1):76-80. PubMed ID: 32284686
    [No Abstract]   [Full Text] [Related]  

  • 9. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administrative practices and procedures; internal agency review of decisions; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(115):32772-4. PubMed ID: 10180279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stakeholder Experiences with the Single IRB Review Process and Recommendations for Food and Drug Administration Guidance.
    Corneli A; Dombeck CB; McKenna K; Calvert SB
    Ethics Hum Res; 2021 May; 43(3):26-36. PubMed ID: 34019339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemptions and Limited Institutional Review Board Review: A Practical Look at the 2018 Common Rule Requirements for Exempt Research.
    Walch-Patterson A
    Ochsner J; 2020; 20(1):87-94. PubMed ID: 32284688
    [No Abstract]   [Full Text] [Related]  

  • 15. The Final Rule: When the Rubber Meets the Road.
    O'Rourke PP
    Am J Bioeth; 2017 Jul; 17(7):27-33. PubMed ID: 28661755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exemption of certain research and demonstration projects from regulations for protection of human research subjects--DHHS. Notice of proposed rulemaking.
    Fed Regist; 1982 Mar; 47(55):12276-7. PubMed ID: 10261479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of human subjects; standards for institutional review boards for clinical investigations--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8958-79. PubMed ID: 10249529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of human subjects; informed consent; standards for institutional review boards for clinical investigations--FDA. Proposed rule.
    Fed Regist; 1988 Nov; 53(218):45678-82. PubMed ID: 10290533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U.S. Federal Regulations for emergency research: a practical guide and commentary.
    McRae A; Weijer C
    Acad Emerg Med; 2008 Jan; 15(1):88-97. PubMed ID: 18211320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.